BR112014016926A2 - composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais - Google Patents

composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais

Info

Publication number
BR112014016926A2
BR112014016926A2 BR112014016926A BR112014016926A BR112014016926A2 BR 112014016926 A2 BR112014016926 A2 BR 112014016926A2 BR 112014016926 A BR112014016926 A BR 112014016926A BR 112014016926 A BR112014016926 A BR 112014016926A BR 112014016926 A2 BR112014016926 A2 BR 112014016926A2
Authority
BR
Brazil
Prior art keywords
trypanosomiasis
animals
treatment
pharmaceutical composition
concentration
Prior art date
Application number
BR112014016926A
Other languages
English (en)
Other versions
BR112014016926A8 (pt
Inventor
Gonzalez Cordero Auristela
Alberto Ochoa Roviro
Original Assignee
Investig Farmaceuticas Y Veterinarias S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016926(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Investig Farmaceuticas Y Veterinarias S L filed Critical Investig Farmaceuticas Y Veterinarias S L
Publication of BR112014016926A2 publication Critical patent/BR112014016926A2/pt
Publication of BR112014016926A8 publication Critical patent/BR112014016926A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communication Control (AREA)

Abstract

resumo "composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais" composição farmacêutica que compreende cloreto de isometamidio numa concentração entre 1 e 4 % (peso/volume), isopropilidenoglicerol ou glicerinformal numa concentração entre 40 e 95 % (peso/volume), um poliol numa concentração entre 0 e 50 % (peso/volume), 15-hidroxiestearato de polietilenoglicol numa concentração entre 0,5 e 7 % (peso/volume), em solução juntamente com excipientes farmaceuticamente aceitáveis, para o tratamento da tripanossomíase em animais. a composição farmacêutica é uma solução injetável pronta para usar e pode ser administrada por via intravenosa, subcutânea ou intramuscular em ruminantes, equídeos e camelídeos. a composição pode compreender ainda agentes antiparasitários, como a ivermectina, numa concentração entre 1 e 5 % (peso/volume) para o tratamento da tripanossomíase e eliminação de parasitas gastrointestinais e pulmonares em animais.
BR112014016926A 2012-01-24 2012-07-19 composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais BR112014016926A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201230092A ES2416004B1 (es) 2012-01-24 2012-01-24 Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales.
PCT/ES2012/070550 WO2013110830A1 (es) 2012-01-24 2012-07-19 Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales

Publications (2)

Publication Number Publication Date
BR112014016926A2 true BR112014016926A2 (pt) 2017-06-13
BR112014016926A8 BR112014016926A8 (pt) 2017-07-04

Family

ID=46963763

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016926A BR112014016926A8 (pt) 2012-01-24 2012-07-19 composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais

Country Status (16)

Country Link
AP (1) AP2014007798A0 (pt)
AR (1) AR089037A1 (pt)
BR (1) BR112014016926A8 (pt)
CL (1) CL2014001780A1 (pt)
CO (1) CO6990714A2 (pt)
CR (1) CR20140278A (pt)
DO (1) DOP2014000161A (pt)
EC (1) ECSP14010152A (pt)
ES (1) ES2416004B1 (pt)
GT (1) GT201400159A (pt)
MA (1) MA35868B1 (pt)
MX (1) MX2014008172A (pt)
NI (1) NI201400075A (pt)
PE (1) PE20141472A1 (pt)
UY (1) UY34479A (pt)
WO (1) WO2013110830A1 (pt)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024008B (en) * 1978-06-28 1983-02-16 Merck & Co Inc Compositions for treating trypanosomiasis infections
GB8805286D0 (en) * 1988-03-05 1988-04-07 Schering Agrochemicals Ltd Trypanocides
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
DE19854143A1 (de) * 1998-11-24 2000-05-25 Chambord Ltd Pharmazeutisches Präparat mit trypanozider und blutschizontozider Wirkung
FR2819188B1 (fr) * 2001-01-08 2003-03-14 Virbac Sa Compositions pulverulentes ou granulees hydrosolubles, a base de phenanthridines et leurs utilisations
AR060926A1 (es) * 2007-05-14 2008-07-23 Ciriaco Quiroga Solucion anestesica transparente de propofol, con baja irritacion venosa.
KR20080102010A (ko) * 2007-05-17 2008-11-24 대원제약주식회사 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
WO2011042565A2 (en) * 2009-10-09 2011-04-14 Instituut Voor Tropische Geneeskunde Antiprotozoal activity

Also Published As

Publication number Publication date
DOP2014000161A (es) 2014-08-15
AP2014007798A0 (en) 2014-07-31
CO6990714A2 (es) 2014-07-10
NI201400075A (es) 2015-04-13
UY34479A (es) 2013-07-31
MA35868B1 (fr) 2014-12-01
ECSP14010152A (es) 2015-08-31
WO2013110830A1 (es) 2013-08-01
AR089037A1 (es) 2014-07-23
ES2416004B1 (es) 2014-01-28
BR112014016926A8 (pt) 2017-07-04
GT201400159A (es) 2015-11-19
MX2014008172A (es) 2014-10-06
CR20140278A (es) 2014-12-02
CL2014001780A1 (es) 2014-10-24
ES2416004A1 (es) 2013-07-29
PE20141472A1 (es) 2014-11-05

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
CY1120583T1 (el) Σκευασματα ινσουλινης για γρηγορη προσληψη
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
AR083858A1 (es) Polipeptidos derivados de la il-2 con actividad agonista para la terapia del cancer e infecciones cronicas
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.
BR112015022196A2 (pt) composições de liberação prolongada, que compreendem hidrocodona e acetaminofeno para rápido início e analgesia prolongada, que podem ser administradas independentemente de alimentos
BR112019005224A2 (pt) forma de dosagem para alívio prolongado
BR112015012497A2 (pt) combinações farmacêuticas
BR112014016926A8 (pt) composição farmacêutica que compreende cloreto de isometamidio em solução para o tratamento da tripanossomíase em animais
BR112013016554A2 (pt) métodos e composições úteis para promover sono nos animais
BR112015015938A2 (pt) uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto
BR112015013223A2 (pt) composição farmacêutica
RU2013150192A (ru) Метапневмовирус птиц в онколизисе
PH12016500563A1 (en) 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]